ADA 2013: Major Players Present Data On Insulins, GLP-1s, SGLT-2s
This article was originally published in The Pink Sheet Daily
The annual ADA conference will include data from a slew of companies, but analysts are most interested in the presentations from the biopharmas that already dominate the market and are expected to maintain their market share in the long-term.
You may also be interested in...
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.